Jakimovski D, Kavak KS, Zakalik K, McGraw C, et al. Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study. J Neurol Sci 2023;455:122781.
PMID: 37979415